BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BC Innovations | Sep 28, 2017
Product R&D

Wave’s purity progress

Wave Life Sciences Ltd. ’s latest data releases provide the fullest view to date into how the company synthesizes its stereopure oligos and the benefits that can be derived from the chemistry. But whether the...
BC Innovations | Aug 24, 2017
Emerging Company Profile

Heartfelt WISPER

HaYa Therapeutics is using antisense oligonucleotides to target the lncRNA WISPER to treat cardiac fibrosis caused by cardiovascular diseases such as myocardial infarction. Because WISPER expression is confined to the heart, the newco is betting...
BC Innovations | Jul 10, 2017
Distillery Therapeutics


INDICATION: Myocardial infarction (MI) Patient sample and mouse studies suggest antisense oligonucleotides (ASOs) targeting the long non-coding RNA (lncRNA) WISPER could help treat MI and MI-associated cardiac fibrosis. In intraventricular septum samples from aortic stenosis...
BC Innovations | Nov 17, 2016
Translation in Brief

Point taken

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) has identified an siRNA-like mechanism that may explain the unexpected potency and pinpoint specificity of its third-generation antisense (3GA) DNA technology, which allows for selective silencing of disease-causing alleles. Antisense oligonucleotides...
BioCentury | Feb 15, 2016
Product Development

High fidelity

Wave Life Sciences Ltd. has set its sights on rare neuromuscular and CNS diseases where its stereopure nucleic acid technology could confer safety and efficacy advantages over competing programs. Wave was formed in 2012 from...
BC Innovations | Oct 8, 2015
Translation in Brief

Heteroduplicity's lure

A collaboration between researchers from Tokyo Medical and Dental University and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) has produced a method to enhance the therapeutic index of antisense oligonucleotides by converting the single-stranded molecules into double-stranded...
BC Week In Review | Sep 15, 2014
Company News

Genomic Health, New England Biolabs deal

New England Biolabs received an exclusive license to use Genomic Health's ribosomal RNA (rRNA) depletion technology, which New England Biolabs will use it is NEBNext product line of reagents for RNA sequencing sample preparation. New...
BC Innovations | Oct 24, 2013
Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression 1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas...
BC Innovations | Aug 9, 2012
Targets & Mechanisms

Isis takes on myotonic dystrophy

Researchers at the University of Rochester and Isis Pharmaceuticals Inc. have come up with an efficient way to treat symptoms of myotonic dystrophy type 1 in mice using systemically delivered antisense oligonucleotides. 1 The finding...
Items per page:
1 - 10 of 40